TriSalus prices $40M public offering of 9.76M shares at $4.10/share

TriSalus Life Sciences, Inc.

Gross proceeds ~$40.0M from 9,756,100 shares at $4.10/share; net proceeds ~$37.0M (before over-allotment).
Underwriters granted 30-day option to purchase up to 1,463,415 additional shares (15% of offering).
Offering expected to close February 23, 2026; Lake Street Capital Markets sole book-runner.
Net proceeds estimated at ~$42.64M if over-allotment fully exercised.
Proceeds for general corporate purposes including working capital and G&A.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

TriSalus Life Sciences, Inc. entered into Underwriting Agreement with Lake Street Capital Markets, LLC (effective 2026-02-19).

Action: entry
Agreement: underwriting
Counterparty: Lake Street Capital Markets, LLC
Effective: 2026-02-19

Exact text from the filing

On February 19, 2026, TriSalus Life Sciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC (“LSCM”), as representative of the underwriters named therein (the “Underwriters”), relating to the public offering (the “Offering”) of 9,756,100 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), at a price to the public of $4.10 per Share (the “Offering Price”).

View on SEC.gov

280 material agreements filed in the last 30 days. Browse all material agreements →

TriSalus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-007598

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.